Patents by Inventor Attilio Tomasi

Attilio Tomasi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
    Patent number: 11091469
    Abstract: The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: August 17, 2021
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Ilaria Candiani, Giovanni Ottaiano, Attilio Tomasi
  • CRYSTALLINE FORM OF N-[5-(3,5-DIFLUORO-BENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-PYRAN-4-YLAMINO)-BENZAMIDE
    Publication number: 20200325122
    Abstract: The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 15, 2020
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Ilaria CANDIANI, Giovanni OTTAIANO, Attilio TOMASI
  • Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
    Patent number: 10738037
    Abstract: The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: August 11, 2020
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Ilaria Candiani, Giovanni Ottaiano, Attilio Tomasi
  • Safe and efficient process for the preparation of carmustine
    Patent number: 10519104
    Abstract: Carmustine may be safely and efficiently produced by reacting 2-chloroethylamine hydrochloride and 1,1?-carbonyldiimidazole to afford 1,3-bis(2-chloroethyl)-1-urea, followed by nitrosation to give the final product.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: December 31, 2019
    Assignee: NerPharMa S.r.l.
    Inventors: Attilio Tomasi, Ilaria Candiani, Francesco Corcella, Francesco Saverio Caldarelli
  • NEW CRYSTALLINE FORM OF N-[5-(3,5-DIFLUORO-BENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-PYRAN-4-YLAMINO)-BENZAMIDE
    Publication number: 20190169173
    Abstract: The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.
    Type: Application
    Filed: May 18, 2017
    Publication date: June 6, 2019
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Ilaria CANDIANI, Giovanni OTTAIANO, Attilio TOMASI
  • SAFE AND EFFICIENT PROCESS FOR THE PREPARATION OF CARMUSTINE
    Publication number: 20170253557
    Abstract: Carmustine may be safely and efficiently produced by reacting 2-chloroethylamine hydrochloride and 1,1?-carbonyldiimidazole to afford 1,3-bis(2-chloroethyl)-1-urea, followed by nitrosation to give the final product.
    Type: Application
    Filed: February 28, 2017
    Publication date: September 7, 2017
    Applicant: NerPharMa S.r.l.
    Inventors: Attilio TOMASI, Ilaria Candiani, Francesco Corcella, Francesco Saverio Caldarelli
  • CRYSTALLINE NEMORUBICIN HYDROCHLORIDE
    Publication number: 20100069317
    Abstract: This invention relates to a novel crystalline polymorphic form of nemorubicin hydrochloride dihydrate, useful for the preparation of pharmaceutical composition for the treatment of tumors. A process for preparing this novel polymorphic form, named form A, is within the scope of the present invention.
    Type: Application
    Filed: June 29, 2007
    Publication date: March 18, 2010
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Romualdo FORINO, Natale Alvaro BARBUGIAN, Attilio TOMASI, Giuseppina VISENTIN, Marco CATTANEO, Massimo ZAMPIERI
  • Crystalline polymorphic form of irinotecan hydrochloride
    Publication number: 20060046993
    Abstract: This invention relates to a novel crystalline polymorphic form of irinotecan hydrochloride. A process for preparing this novel polymorphic form, pharmaceutical compositions comprising it as an active ingredient and the use of the same and its pharmaceutical compositions as a therapeutic agent is also within the scope of the present invention.
    Type: Application
    Filed: September 1, 2004
    Publication date: March 2, 2006
    Applicant: Pharmacia Italia S.p.A.
    Inventors: Romualdo Forino, Natale Barbugian, Massimo Zampieri, Attilio Tomasi
  • Process for preparing crystalline Form I of cabergoline
    Patent number: 6953854
    Abstract: A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals. A new solvate form V of cabergoline, useful as an intermediate, is also provided.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: October 11, 2005
    Assignee: Pharmacia
    Inventors: Attilio Tomasi, Stefania Magenes, Mario Ungari, Giuliano Ramella, Gianfranco Pallanza
  • Crystalline form II of cabergoline
    Patent number: 6800635
    Abstract: Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from s solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline forms I and II in a solvent at a temperature below 30° C.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: October 5, 2004
    Assignee: Pharmacia Italia, S.p.A.
    Inventors: Attilio Tomasi, Stefania Magenes, Giuliano Ramella, Mario Ungari, Marco Pandolfi
  • Process for preparing crystalline form I of cabergoline
    Publication number: 20040092744
    Abstract: A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals.
    Type: Application
    Filed: October 31, 2003
    Publication date: May 13, 2004
    Applicant: Pharmacia Italia, S.p. A.
    Inventors: Attilio Tomasi, Stefania Magenes, Mario Ungari, Giuliano Ramella, Gianfranco Pallanza
  • Process for preparing crystalline form I of cabergoline
    Patent number: 6727363
    Abstract: A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals. A new solvate form V of cabergoline, useful as an intermediate, is also provided.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: April 27, 2004
    Assignee: Pharmacia Italia SPA
    Inventors: Attilio Tomasi, Stefania Magenes, Mario Ungari, Giuliano Ramella, Gianfranco Pallanza
  • Crystalline form II of cabergoline
    Publication number: 20040072855
    Abstract: Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from s solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline forms I and II in a solvent at a temperature below 30° C.
    Type: Application
    Filed: October 31, 2003
    Publication date: April 15, 2004
    Applicant: Pharmacia Italia, S.p.A.
    Inventors: Attilio Tomasi, Stefania Magenes, Giuliano Ramella, Mario Ungari, Marco Pandolfi
  • Crystalline form II cabergoline
    Patent number: 6673806
    Abstract: Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from a solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline Forms I and II in a solvent at a temperature below about 30° C.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: January 6, 2004
    Assignee: Pharmacia Italia S.p.A.
    Inventors: Attilio Tomasi, Stefania Magenes, Giuliano Ramella, Mario Ungari, Marco Pandolfi
  • Crystalline form II cabergoline
    Publication number: 20030187013
    Abstract: Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from a solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline Forms I and II in a solvent at a temperature below about 30° C.
    Type: Application
    Filed: January 16, 2003
    Publication date: October 2, 2003
    Inventors: Attilio Tomasi, Stefania Magenes, Giuliano Ramella, Mario Ungari, Marco Pandolfi
  • Process for preparing crystalline from I of cabergoline
    Publication number: 20030149067
    Abstract: A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals. A new solvate form V of cabergoline, useful as an intermediate, is also provided.
    Type: Application
    Filed: February 3, 2003
    Publication date: August 7, 2003
    Inventors: Attilio Tomasi, Stefania Magenes, Mario Ungari, Giuliano Ramella, Gianfranco Pallanza